This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dendreon: Third Quarter Earnings Preview

SEATTLE ( TheStreet) -- Dendreon (DNDN) will provide investors with another Provenge sales update when the company reports third quarter results Wednesday.

Analysts, on average, are expecting Provenge sales of just under $24 million. Dendreon is expected to post a net loss of 44 cents a share in the quarter, according to Thomson Reuters.

Dendreon's third-quarter report comes just two weeks before the U.S agency in charge of Medicare and Medicaid convenes a panel meeting to assess the use of Provenge in prostate cancer patients. Dendreon shares have been volatile going into this panel meeting because of concerns that Medicare officials could decide to restrict or limit reimbursement of Provenge.

The U.S. Food and Drug Administration approved Provenge on April 29. Provenge is the first cancer drug approved that works by activating a patient's own immune system to fight the disease. Yet the Provenge launch isn't typical since Dendreon can't make enough to satisfy patient demand. The company long ago told investors that limited manufacturing capacity would only allow about 2,000 patients to be treated in the first 12 months of the launch.

On Wednesday, Dendreon is expected to update investors on the progress being made to expand its New Jersey manufacturing plant and build out two new plants in Atlanta and Orange County, Calif., respectively. Dendreon is expected to be at full manufacturing capacity for Provenge in the middle of 2011.

Dendreon should also offer an update on the number of prescriptions written for Provenge. In August, the company said doctors wrote 500 Provenge prescriptions in the first three months of the drug's launch, which signaled strong demand for the drug.

Dendreon shares were up 21 cents to $36.71 in Monday trading.

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
DNDN $0.06 -6.02%
AAPL $124.75 0.00%
FB $80.78 0.00%
GOOG $524.05 0.00%
TSLA $206.79 0.00%

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs